02509 QYUNS-B
- 24.100
- +0.400+1.69%
QYUNS-B News
Quanxin Biotechnology-B (02509.HK): Phase II clinical trial data for QX005N injection in the treatment of nodular prurigo (PN) was released at the 29th Annual Conference of the Chinese Society of Dermatology.
On June 14, Gelunhui announced that the phase II clinical trial data (CTR20223174) of QX005N injection for the treatment of nodular pruritus (PN) was orally presented at the 29th Annual Conference of Chinese Dermatology Association. This trial is the first domestic clinical trial of biological drugs for PN indication conducted by Chinese companies. Based on the trial data, QX005N was included in the list of breakthrough therapies by the Center for Drug Evaluation of the National Medical Products Administration on January 31 this year. This clinical study is a multicenter, randomized trial.
Qyuns Therapeutics Enrolls First Subject in Phase 3 Trial of Skin Disease Drug
Qyuns Therapeutics (HKG:2509) enrolled the first subject for its phase 3 clinical trial of QX005N, a treatment for prurigo nodularis, a chronic and inflammatory skin disease, according to a Wednesday
Changes in Hong Kong stocks | Quanxin Bio-B (02509) rose more than 7% QX005N Tuberous Prurigo Phase III Clinical Trial Successfully Achieved First Patient Enrollment
Quanxin Bio-B (02509) rose more than 7%. As of press release, it rose 6.95% to HK$29.25, with a turnover of HK$2,5592 million.
Zhitong Hong Kong stocks have known for a long time | Pig breeding is fully profitable State Council: Gradually lift restrictions on NEV purchases in various regions
The State Council issued the “2024-2025 Action Plan for Energy Conservation and Carbon Reduction”, which mentions strengthening the regulation of production capacity and output in the building materials industry. Strictly implement the replacement of cement and flat glass production capacity.
Quanxin Bio-B (02509.HK): QX005N Tuberous Prurigo Phase III Clinical Trial Successfully Achieved First Patient Enrollment
On May 29, Ge Longhui | Quanxin Bio-B (02509.HK) announced that on May 29, 2024, the QX005N injection phase III clinical trial (registration number: CTR20241660) independently developed by the company reached the enrollment of the first test subjects. This is the first phase III clinical trial for PN indications carried out by a Chinese company in China. On January 31, 2024, QX005N was included in the list of breakthrough therapeutic varieties by the Drug Evaluation Center of the State Drug Administration. The corresponding indication is PN. This test is an evaluation of the QX00
China Grants Investigational New Drug Status to Qyuns Therapeutics' Urticaria Treatment
China's medical products administrator granted investigational new drug status to Qyuns Therapeutics' (HKG:2509) QX013N for chronic spontaneous urticaria, a skin condition, according to a Thursday fil
Quanxin Bio-B (02509.HK) obtained QX013N clinical trial approval for a new drug for the treatment of chronic spontaneous urticaria in China
Gelonghui, May 9, 丨 Quanxin Bio-B (02509.HK) announced that on May 9, 2024, the humanized IgG1 monoclonal antibody Qx013n independently developed by the company obtained a new drug clinical trial license (acceptance number: CXSL2400165) from the China National Drug Administration Drug Evaluation Center for the treatment of chronic spontaneous urticaria (CSU). Qx013n is China's first biopharmaceutical candidate targeting c-Kit. CSU is a common chronic inflammatory skin disease characterized by spontaneous skin lumps and/or angioedema, which lasts longer than
荃信生物-B：2023年度報告
[Monthly IPO Report] The Hong Kong stock IPO market is the starting force, Fujing China Holdings overbought more than 293 times, and Hongji Group made a maximum profit of 4,800 yuan in the first sale
After February's silence, the Hong Kong stock IPO market exploded in March. Seven companies went public one after another, and only 1 went bankrupt. Source: Jinwu Financial News March Fund-raising King - Although the number of listed companies has clearly picked up, it still lacks the boost of large companies. Judging from the scale of fund-raising, the 7 new shares introduced in March were small in overall size, and the Miko Group, which raised the highest amount of capital, was only HK$918 million. According to reports, the company is the third-largest potash enterprise in China and has market advantages. However, industry growth is expected to be in the low single digits. The market for the company's main product, potassium chloride, is also relatively concentrated, and development needs to face challenges. Sino-Thai International said earlier that the government
QYUNS-B: FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023
Changes in Hong Kong stocks | Quanxin Bio-B (02509) rose by more than 14%. The company is deeply involved in the self-exempt circuit, and the QX001S is expected to become the first commercial product
The Zhitong Finance App learned that Quanxin Biotech B (02509) rose by more than 14%. As of press release, it had risen 12.06% to HK$20.35, with a turnover of HK$318.66. According to reports, Quanxin Biotech is a clinical-stage biotechnology company focusing on the development of biotherapies for autoimmune and allergic diseases. The company's core competitiveness is its two core products, QX002N and QX005N, which are independently developed. QX002N is an IL-17A inhibitor. The company has conducted phase III clinical trials for the treatment of ankylosing spondylitis (AS) in China. QX005N is a resistor
Hong Kong Shares Inch Up After China Holds Benchmark Rates Steady; Qyuns Therapeutics Falls 9% on Debut
Hong Kong shares finished fractionally higher on Wednesday on encouraging corporate results, with traders keeping a watchful eye on the future direction of the People's Bank of China's monetary policy
[IPO] Quanxin Biotech (02509) closed at HK$24.5, 23.74% higher than the offering price
Jinwu Financial News | Quanxin Biotech (02509) closed at HK$24.5, 23.74% higher than the offering price. It traded 2,308,200 shares throughout the day, with a turnover of HK$61.6727 million. Excluding handling fees, each lot earns HK$940 for 200 shares. The stock opened at HK$27.4 in early trading, which was 38.38% higher than the offering price. The daily high was HK$28.2, and the lowest price was HK$24.5. The latest total market value is HK$5.441 billion.
Qyuns Therapeutics Raised HK$163.3M in Net Proceeds in Hong Kong IPO
Qyuns Therapeutics Raised HK$163.3M in Net Proceeds in Hong Kong IPO
Qyuns Therapeutics Shares at HK$26.15 Vs IPO Price of HK$19.80
Qyuns Therapeutics Shares at HK$26.15 Vs IPO Price of HK$19.80
Qyuns Therapeutics Up 32% at Midday After Hong Kong Debut
Qyuns Therapeutics Up 32% at Midday After Hong Kong Debut
Quanxin Bio-B (2509.HK) will be listed now. Let's discuss the investment logic of the “Three Good Students”
Today, the “First Hong Kong Stock Exemption” Quanxin Biotech was officially listed on the main board of the Hong Kong Stock Exchange, with an issue price of HK$19.80 per share. Judging from the previous stock offering performance, Quanxin Biotech received 163.15 times oversubscription in the Hong Kong public sale, making it the IPO project with the highest subscription ratio in Hong Kong since 2022. The popular subscription situation already reflects the market's recognition of the company's past performance and expectations for future growth potential. Let's take a closer look at the long-term value growth logic after listing. Support from professional investment institutions, capital support shows confidence. For most investors, the innovative pharmaceutical industry is high
Qyuns Therapeutics Opens 38% Higher in Hong Kong Trading Debut
Qyuns Therapeutics (HKG:2509) opened 38.4% higher at HK$27.40 in its first trading day on the Hong Kong bourse Wednesday. The clinical-stage biotechnology company offered 12,046,400 shares and priced
First day of IPO | Quanxin Biotech (02509) first listed and opened 38.38% higher in early trading
According to the announcement, Quanxin Biotech B (02509) was listed for the first time. According to the announcement, the company sold 1.2 million shares globally, with a final sale price of HK$19.8 per share. The net proceeds from the global sale were approximately HK$163 million, or 200 shares per lot. As of press release, it rose 38.38% to HK$27.4, with a turnover of HK$22.2373 million.
Quanxin Bio-B's public offering of HK$19.80 per share was subscribed 163.15 times
Quanxin Biotech B (02509) announced the allotment results. The company sold 1.2 million shares globally, with the Hong Kong public offering accounting for 17.77% and the international offering accounting for 82.23%. The final sale price was HK$19.8 per share, with a net raise of approximately HK$163 million from the global sale. With 200 shares per lot, H shares are expected to start trading on the Stock Exchange at 9:00 a.m. on March 20, 2024 (Tuesday). Among them, the public sale received 163.15 times the subscription, and the international sale received 0.9965 times the subscription.
Analysis
Price Target
No Data
